Investor Presentaiton
Novo Nordisk Annual Report 2023
Equity statement
at 31 December
DKK million
Balance at the beginning of the year
Net profit
Other comprehensive income
Total comprehensive income
Transfer of cash flow hedge reserve to intangible assets (note 4.3)
Transactions with owners:
Dividends (note 4.2)
Share-based payments (note 5.1)
Purchase of treasury shares (note 4.3)
Reduction of the B share capital (note 4.3)
Tax related to transactions with owners
Balance at the end of the year
Refer to note 4.3 for details of movements in Other reserves.
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information.
53
2023
2022
2021
Share
capital
Treasury
shares
456
(6)
Retained
earnings reserves
80,587 2,449
Other
Total
83,486
Share
capital
462
Treasury Retained
shares
Other
Share
Treasury Retained
Other
earnings reserves
Total
(6) 72,004 (1,714)
70,746
capital
470
shares earnings reserves
Total
(8)
63,774
(911)
63,325
83,683
83,683
55,525
55,525
47,757
47,757
13
(1,173)
(1,160)
615
4,163
83,696
(1,173)
82,523
56,140
4,163
4,778
60,303
146
(816)
(670)
47,903
(816)
47,087
13
13
(31,767)
(31,767)
(25,303)
2,149
2,149
1,539
(25,303)
1,539
(21,517)
1,040
(4)
(29,920)
(29,924)
(6)
(24,080)
(24,086)
(6)
(19,441)
(21,517)
1,040
(19,447)
(5)
5
(6)
6
(8)
8
94
94
287
287
245
245
451
(5)
104,839
1,276
106,561
456
(6)
80,587
2,449
83,486
462
(6)
72,004 (1,714)
70,746View entire presentation